rs4244285 — CYP2C19 *2

CYP2C19*2 - The Clopidogrel Gene

CYP2C19 is a drug-metabolizing enzyme with enormous clinical significance, particularly for the antiplatelet drug clopidogrel (Plavix). The *2 allele¹¹ rs4244285 is the most common loss-of-function variant, rendering the enzyme completely non-functional. This variant carries an FDA black-box warning²² FDA black-box warning
Clopidogrel (Plavix) prescribing label, FDA on the clopidogrel label - one of the clearest examples of pharmacogenomics directly affecting prescribing decisions.

The Mechanism

The CYP2C19*2 variant is a synonymous change (G>A at position 681 in exon 5) that creates an aberrant splice site³³ Despite being synonymous at the protein level, this variant disrupts normal mRNA splicing, producing a truncated, non-functional protein. Although the nucleotide change itself does not alter the encoded amino acid (Pro227=), it introduces a cryptic splice site that shifts the reading frame, leading to a premature stop codon. Homozygous carriers (AA) have no CYP2C19 activity and are classified as poor metabolizers.

The Clopidogrel Crisis

Clopidogrel is a prodrug⁴⁴ A prodrug is inactive until the body converts it to its active form that REQUIRES CYP2C19 to be converted to its active antiplatelet metabolite. Poor metabolizers who take clopidogrel after coronary stent placement have significantly higher rates of stent thrombosis, heart attack, and cardiovascular death. A landmark study by Mega et al.⁵⁵ landmark study by Mega et al.
Mega JL et al. Reduced-function CYP2C19 genotype and risk of cardiovascular events. JAMA, 2010 confirmed this association across multiple trials, leading to the FDA black-box warning⁶⁶ FDA black-box warning
Clopidogrel (Plavix) prescribing label, FDA.

Beyond Clopidogrel

CYP2C19 also metabolizes proton pump inhibitors (PPIs like omeprazole and pantoprazole), certain antidepressants (citalopram, escitalopram, sertraline), and antifungal agents (voriconazole). For PPIs, poor metabolizers actually benefit because the drug stays active longer, providing better acid suppression. For antidepressants, poor metabolizers may need dose reductions.

What You Should Do

If you are a poor metabolizer (AA), the clopidogrel information is potentially life-saving. If you ever need antiplatelet therapy (after a stent, stroke, or peripheral vascular disease), you MUST use an alternative like prasugrel or ticagrelor. Share this information with your cardiologist and keep it in your medical records.